Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Scope Fluidics Spolka Akcyjna's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was -178.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
WAR:SCP's 5-Year ROIIC % is ranked worse than 93.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.745
vs WAR:SCP: -178.31
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Scope Fluidics Spolka Akcyjna 5-Year ROIIC % Related Terms
Scope Fluidics Spolka Akcyjna 5-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCP vs TMO, DHR, IDXX: 5-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna 5-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's 5-Year ROIIC % falls into.
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -47.282 (Dec. 2025) - -11.698 (Dec. 2020) )
/
( 36.128 (Dec. 2025) - 16.172 (Dec. 2020) )
=
-35.584
/
19.956
=
-178.31%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a 5-Year ROIIC % of -178.31 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #177 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 93.2%.
Is Scope Fluidics Spolka Akcyjna's 5-Year ROIIC % too high?
Scope Fluidics Spolka Akcyjna's current 5-Year ROIIC % is -178.31. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #177 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's 5-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #177 out of 190 companies for 5-Year ROIIC %. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Diagnostics & Research company?
A good 5-Year ROIIC % depends on the Medical Diagnostics & Research industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. Scope Fluidics Spolka Akcyjna's current 5-Year ROIIC % is -178.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł128.63, compared to a current price of zł120.00 — trading 6.7% below its estimated fair value. The current 5-Year ROIIC % is -178.31. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current 5-Year ROIIC % is -178.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued.
The current stock price of zł120.00 is trading 6.7% below its estimated GF Value™ of zł128.63.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
5-Year ROIIC %: -178.31
GF Value™: zł128.63 vs. price of zł120.00 (6.7% below fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna Business Description
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
50GF Score
Get the complete analysis for WAR:SCP
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
